KRAS and colorectal adenocarcinoma: Conversely, other reports detected co-existing mutations in 26 out of 140 patients (Tortola et al., 1999), and more recently 26% of 229 patients presented mutations of both KRAS and TP53 (Chow et al., 2016) and a mild correlation was observed between the expression of the KRAS gene and TP53 immunoexpression in colorectal adenocarcinoma (Rachmawati et al., 2019).